The Conversation (0)
March 16, 2022
The common shares of Nirvana Life Sciences Inc., have been approved for listing on the CSE.
Listing and disclosure documents will be available at www.thecse.com on the trading date.
Nirvana Life Sciences Inc. is focused on developing medical products and regimens that address addiction. Nirvana is working on novel formulations of psilocybin and other naturally-sourced psychedelics to treat pain, opioid dependency and other health problems.
The Exchange is accepting Market Maker applications for NIRV. Please email: Trading@theCSE.com
If you have any questions or require further information please contact Listings at (416) 367-7340 or E-mail: Listings@thecse.com
Source
NIRV:CC
INN Article Notification
07 April 2022
Nirvana Life Sciences
Psychedelics for Opioid Addiction Recovery and Pain Management
Psychedelics for Opioid Addiction Recovery and Pain Management Keep Reading...
01 May
Medical Cannabis and Psychedelics Reforms Reshaping Mental Health Markets
The landscape for medical cannabis and psychedelic therapies has rapidly shifted in just a few weeks following recent executive actions in the US. Between the formal rescheduling of medical cannabis to Schedule III and an executive order aimed at accelerating mental health treatments, several... Keep Reading...
24 April
Executive Order Sparks New Phase for Psychedelic Biotech, Risks Remain
On April 18, President Trump was joined by top health officials in the Oval Office to sign Accelerating Medical Treatments For Serious Mental Illness, an executive order to expand research into ibogaine. This signals the strongest federal endorsement yet of psychedelic medicine as an alternative... Keep Reading...
20 April
Numinus Wellness Responds to Trump Executive Order on Psychedelic Therapies
Company's clinical research operations and therapist training programs directly positioned to support accelerated research and commercialization timelinesNuminus Wellness Inc. (OTC: NUMIF) today acknowledged the Executive Order signed by President Donald J. Trump directing United States federal... Keep Reading...
20 April
Emyria Launches Global Services Platform Targeting International Drug Sponsors
Emyria’s established, world-first, unique national clinical delivery network to drive a new services-led revenue stream focused on global drug sponsors.
Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”), a leader in innovative mental health treatments, is pleased to announce the launch of its Empax Global Partnership Program, a new services platform enabling international drug sponsors to access Emyria’s established clinical delivery... Keep Reading...
24 March
Numinus Wellness Provides Update Regarding Listing Status
Numinus Wellness Inc. (TSX: NUMI) (OTC Pink: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with an emphasis on safe, evidence-based psychedelic-assisted therapies, is providing an update regarding its listing status on the... Keep Reading...
13 March
Numinus Wellness Provides Corporate Update
Numinus Wellness Inc. (TSX: NUMI) (OTC: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, is providing a corporate update.Corporate UpdateOver the past year,... Keep Reading...
Latest News
Interactive Chart
Latest Press Releases
Related News
TOP STOCKS
American Battery4.030.24
Aion Therapeutic0.10-0.01
Cybin Corp2.140.00